MedPath

Comparison of Effects of Pitavastatin and Rosuvastatin on Patients With Chronic Heart Failure

Not Applicable
Conditions
heart failure
Registration Number
JPRN-UMIN000007695
Lead Sponsor
Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
30
Inclusion Criteria

Not provided

Exclusion Criteria

receiving treatment with a statin; taking a coenzyme Q10 (CoQ10) prior to the randomization and history of cardiac events. The ethics committee at Chiba University Graduate School of Medicine approved the OPAL protocol, which adhered according to the principles of the Helsinki Declaration

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
serum LDL-cholesterol, total CoQ10 and the following biomarkers; markers of inflammation (high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha ) and pentraxin 3 (PTX3)), marker of the severity of heart failure (N-terminal pro-brain natriuretic peptide (NT-proBNP), tenascin C, and high-sensitivity cardiac troponin T (hs-TnT)), a marker of oxidative stress (urinary 8-isoprostane) and a marker of chronic kidney disease (urinary albumin to creatinine ratio (UACR)) at 12 weeks
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath